IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
9.55 ^USD	-4.93%		+3.58%	+14.92%

09/05	RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	MT
08/05	Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000	MT

IGM Announces the Appointment of Kathy Miller as Vice President, Antibody Discovery

August 07, 2020 at 01:55 am IST

IGM announced the appointment of Kathy Miller, Ph.D., as Vice President, Antibody Discovery. Prior to joining IGM, Dr. Miller served as Vice President, Biotherapeutics at Five Prime Therapeutics from 2015-2020. She has also served in various scientific and leadership roles at Novartis Institutes for Biomedical Research, and at Merck Research Laboratories at the former DNAX/Schering Plough site.

Latest news about IGM Biosciences, Inc.

RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	09/05	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000	09/05	MT
IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	09/05	CI
IGM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	17/04	MT
IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	17/04	CI
North American Morning Briefing : Stocks Set for -2-	28/03	DJ
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating	12/03	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000	08/03	MT
Igm Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/03	CI
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
North American Morning Briefing : Stock Futures -2-	12/02	DJ
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept	09/02	MT
Transcript : IGM Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	11/01
North American Morning Briefing : Stock Futures -2-	18/12	DJ
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20	15/12	MT
IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from NASDAQ Biotechnology Index	15/12	CI
North American Morning Briefing : Futures Pause -2-	08/12	DJ
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11	07/12	MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating	06/12	MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk	06/12	MT
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization	06/12	MT
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap	06/12	DJ
IGM Biosciences to Reduce Workforce by 22%, Pause Hematologic Oncology Clinical Development	06/12	MT
Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%	06/12	CI

Chart IGM Biosciences, Inc.

Duration

Period

More charts

Company Profile

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Companyâs pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Companyâs development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for IGM Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.55 USD

Average target price

21.4 USD

Spread / Average Target

+124.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IGM BIOSCIENCES, INC.	+14.92%	56Cr
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.15%	11TCr
BIONTECH SE	-8.14%	2.34TCr
ARGENX SE	-1.69%	2.18TCr
GENMAB A/S	-10.60%	1.81TCr
WUXI APPTEC CO., LTD.	-41.25%	1.67TCr
BEIGENE, LTD.	-15.33%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+5.80%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+28.03%	1.17TCr

Bio Therapeutic Drugs